CircAID-p-seq for Oxford Nanopore Technologies

Selective sequencing of short RNAs bearing a 3’P or 2′,3′ cP end
Quick (1-day) high quality library preparation
No library PCR amplification bias
Suitable for RNA footprinting, Ribosome Profiling and transcriptome analysis.

AHARIBO for de novo proteome

Isolation of nascent peptides associated with active polyribosomes
Easy and quick pull-down approach
Parallel RNA and protein analysis if combines to AHARIBO for RNA
Suitable for downstream mass spec. and Western blot analysis.

AHARIBO for RNA

Isolation of active polyribosomes and associated RNAs
Easy and quick pull-down approach
Parallel RNA and protein analysis if combines with AHARIBO for proteome
Suitable for downstream RNAseq and qPCR

RiboLace Ribo-Seq kit library prep

Isolation of active ribosomes
Antibody-free and tag-free pull-down approach
Input material 40x less than standard Ribosome Profiling protocols
Optimized protocol for library preparation

The Specialized Ribosome Technology Platform

New and better information for scientists, toward novel therapeutic strategies in cancer and congenital disorders. We design, we produce and we provide research tools for gene expression analysis at the ribosomal level

For customers

We are engaged with customers at every step of the way.

For investors

Pushing Forward With Collaborative R&D Models In Biotech.

Intellectual property

A platform of opportunities.

Products

RiboLace kit – improving ribosome profiling experiments

A novel method based on an original puromycin-containing molecule capable of isolating active ribosomes by means of an antibody-free and tag-free pull-down approach. [25% discount until Dec2020]

Library Prep for ribosome profiling

Library prep for ribosome profiling kit is used to prepare libraries starting from Ribosome Protected Fragments (RPFs) isolated using RiboLace Ribo-Seq or other protocols. [25% discount until Dec2020]

CircAID-p-seq for Oxford Nanopore Technologies

CircAID-p-seq kit is designed for quick (1-day) high-quality library preparation for short RNAs bearing a 3’-phosphate/2’,3’-cyclic phosphate compatible with Oxford Nanopore platform.

Small molecules for monitoring protein synthesis

Tools for monitoring protein synthesis and studying translation on the protein-exposed ribosome surface in research, industrial and medical fields.

AHARIBO RNA

Specific for the analysis of translatome through the isolation of active ribosomes [25% discount until Dec2020]

AHARIBO Protein

AHARIBO for de novo proteome analysis is dedicated to the analysis of newly synthesized proteins [25% discount until Dec2020]

Micro and nanoparticles for biological applications

A selection of micro and nanoparticles based on silica, gold, graphene, and hydrogels for applications of in biology and biotechnology.

About us

IMMAGINA BioTechnology s.r.l (The Ribosome Company) is a company operating in the MedTech sector of Genomics, Proteomics and Enabling Technology, that is incubated in the Laboratory for Biomolecular Sequence and Structure Analysis for Health in Trento (Italy). Our mission is to deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers. IMMAGINA was founded in 2014, when the founders started to develop RiboLace^TM, the only technology that enables the capture of active ribosomes. RiboLace is on the market from November 2018. Starting from 2016, thanks to the levering investments from private investors (of whom the most relevant one is BAN/TN, TBA network and the Herman Hauser Investment) and the recruitment of new experienced scientists, two new technologies for translatome analysis (AHARIBO^TM and circAID-p-seq^TM) were developed and finally launched on the market at the end of 2019. IMMAGINA offers a platform of products with the potential to accelerate the path toward the discovery of novel therapeutic strategies.

Mission

We deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers.

The Ribosome Company

Solutions

IMMAGINA designed, developed and commercialize a Platform Technology focused on Ribosome to isolate and analyse active ribosomes and the associated RNA molecules

Vision

IMMAGINA ambition is to deliver smart solutions for truer gene expression analysis in research and pharma labs, to support life science worldwide. We are working to provide you with the best picture of gene expression. Because the message is only part of the story.

Supporters & partners

Team

Wants to join the startup company to help accomplish our mission?

Careers

THERE ARE NO CURRENT OPEN POSITIONS

News

Immagina Biotech and Tri-I Biotech announce distribution agreement

Immagina Biotech is very pleased to announce the appointment of Tri-I Biotech Inc as its official distributor in Taiwan to further expand and grow its business operations in Asia.

Nature Pubblication: SMN-primed ribosomes modulate the translation of transcripts related to Spinal Muscular Atrophy

RiboLace to study Spinal Muscular Atrophy.
SMN-primed ribosomes modulate the translation of transcripts related to Spinal Muscular Atrophy

Winners of the Immagina Ribo-Omics Grant Challenge 2020.

We are excited to share the winners of the
Immagina Ribo-Omics Grant Challenge 2020.

Online webinar: Spinal Muscular Atrophy: lost in translation?

IMMAGINA BIOTECHNOLOGY and TomaLab are excited to host a series of free live scientific webinars. During the webinars, prestigious speakers will present their recent researches carried out by the use of IMMAGINA BIOTECH products for the study of translational control of gene expression and diseases.

Officially announcing the collaboration between IMMAGINA Biotechnology and Genexa!

We are working together to develop a powerful data analysis tool for the only product available for 3’ phospho-RNA sequencing with ONT platform, CircAID-p-seq! Genexa is a service provider for bioinformatic analyses based in Zurich, Switzerland. Genexa’s services are centered around the analysis of third- and next-generation genomics data and the development of novel data […]

EIT headstart grant to investigate circAID-p-seq applications in the pharma sector

We are glad to announce that we were awarded the EIT headstart grant to further investigate circAID-p-seq applications in the pharma sector